Stopping as a Clinical Transition

A review argues that coming off these drugs should be treated as a high-risk clinical transition rather than a treatment endpoint.^[1] It also reports something a review we covered last week said did not yet exist: an association between early discontinuation and later cardiovascular disease. Both statements are defensible, and the gap between them is worth understanding.

What the review reports

• HbA1c normalizes within 12 to 18 months of stopping — that is, returns to where it was.
• Discontinuation before one year is associated with increased risks of coronary artery disease and heart failure, compared with continuing.
• Weight recurrence is biological: reactivation of orexigenic pathways and adaptive thermogenesis.
• No validated tapering strategies exist. Nobody has established how to stop safely.

The disagreement worth naming

We recently covered a Nature Reviews Endocrinology review that made the cardiovascular argument carefully and then said plainly that few data are available regarding the incidence of hard outcomes in people discontinuing such drugs — in the cardiovascular cost of stopping.

One review says the outcome data barely exist. The other reports what it says. Both can be right.

The reconciliation is not complicated: an association can exist in observational records while still being thin, unadjusted for the reasons people stop, and far short of what anyone would want before advising a patient. A review emphasizing the absence of good evidence and a review reporting the available evidence are describing the same weak literature from two directions.

The practical consequence is that the cardiovascular risk of stopping is a real hypothesis with weak support, and anyone presenting it as established — in either direction — is going beyond what exists.

The mechanism is the useful part

Where this review adds something our earlier coverage lacked is in explaining why weight returns. Two processes are named: reactivation of orexigenic pathways — the signaling that drives hunger, suppressed while on the drug and released when it stops — and adaptive thermogenesis, the reduction in energy expenditure that follows weight loss and persists.

That framing matters because of what it displaces. Weight returning after stopping is routinely read, including by patients about themselves, as a failure of discipline. Described as orexigenic reactivation against a lowered metabolic rate, it is a physiological response to an intervention being withdrawn — which is what the trial evidence has consistently shown.

What to do with 'no validated tapering strategies'

That phrase is the honest center of the review. There is no evidence-based way to come off these drugs, and the authors suggest structured multidisciplinary transitions combining pharmacological, behavioral and psychological support as the best available approach — explicitly in the absence of validated alternatives.

What does have randomized support is not stopping. Reducing to a lower labeled dose held much of the loss while tripling the need for rescue therapy, and a pill maintained 79.3% of the reduction against 37.6% on placebo — covered in the maintenance trial and the oral handover. Neither is a taper. Both are alternatives to a full stop.

And in ordinary care, the average person who stopped regained very little in a year — because most did something else afterward, covered in what people actually do after stopping. The catastrophic framing is not supported; the “treat it as a transition” framing is.